Compare ResMed Inc. (RMD) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard S&P 500 ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 56.4× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard S&P 500 ETF for 55 Days on average.
| RMD | VOO | |
|---|---|---|
Market Cap | $31.89B | $1.80T |
Volume | 618,314 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $275.96 | $716.17 |
52-Week Low | $182.82 | $580.93 |
Typical Hold Time | 51 Days | 55 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
VOO trades at $711.37, down 0.43% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional support despite a 46.9% increase in short interest reported by Defense World on October 3, 2026. Recent news highlights VOO's role as a core holding for long-term wealth building, with dividend payments scheduled for September 30, 2026.
VOO offers diversified exposure to S&P 500 companies with strong earnings growth projections of 35% for 2026. While short-term volatility may persist amid Federal Reserve policy uncertainty, the ETF remains well-positioned for investors seeking broad market participation. Key risks include potential earnings growth deceleration to 15% in 2027 and broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
